Photo of Tiffany A. Hetland

Tiffany’s practice touches all aspects of the rapidly changing healthcare delivery system, from medical care providers to hospitals, pharmaceutical manufacturers and insurance plans.

On July 13, the Centers for Medicare & Medicaid Services (“CMS”) put out its 2018 Medicare Hospital Outpatient Prospective Payment System Proposed Rule. The Rule proposes, among other things, to dramatically reduce Medicare Part B reimbursement of drugs procured by hospitals at 340B prices—from the current rate of Average Sales Price (“ASP”) plus 6 percent to ASP minus 22.5 percent.  By CMS’s estimate, this could result in savings to the Part B program of $900 million and a corresponding cut to the 340B hospitals which currently receive those payments (and ostensibly use them in furtherance of the 340B program’s goal of assisting safety net providers in stretching their scarce resources).  
Continue Reading CMS Proposes Drastic Reduction to Medicare Part B Reimbursement of 340B Drugs